Literature DB >> 34181056

JAK2V617F mutation in patients with β-thalassemia disease: prevalence and clinical characteristics.

Nattiya Teawtrakul1, Siriyakorn Chansai2,3, Supawadee Yamsri3, Piti Ungarreevittaya4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34181056     DOI： 10.1007/s00277-021-04582-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  7 in total

1.  Absence of JAK2 V617F mutation in thalassemia intermedia patients.

Authors:  Ali Taher; Dina Shammaa; Ali Bazarbachi; Doha Itani; Ghazi Zaatari; Layal Greige; Zaher K Otrock; Rami A R Mahfouz
Journal:  Mol Biol Rep       Date:  2008-09-10       Impact factor: 2.316

2.  Absence of JAK2V617F mutation in patients with beta-thalassemia major and thrombocytosis due to splenectomy.

Authors:  E Vlachaki; A Kalogeridis; N Neokleous; V Perifanis; F Klonizakis; E Ioannidou; I Klonizakis
Journal:  Mol Biol Rep       Date:  2011-12-28       Impact factor: 2.316

3.  Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.

Authors:  Ali T Taher; Zeynep Karakas; Elena Cassinerio; Noppadol Siritanaratkul; Antonis Kattamis; Aurelio Maggio; Stefano Rivella; Norbert Hollaender; Bruyère Mahuzier; Brian Gadbaw; Yesim Aydinok
Journal:  Blood       Date:  2017-11-02       Impact factor: 22.113

Review 4.  The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia.

Authors:  Stefano Rivella
Journal:  Blood Rev       Date:  2012-04       Impact factor: 8.250

5.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

6.  Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.

Authors:  John B Porter; Maria Domenica Cappellini; Antonis Kattamis; Vip Viprakasit; Khaled M Musallam; Zewen Zhu; Ali T Taher
Journal:  Br J Haematol       Date:  2016-12-05       Impact factor: 6.998

7.  Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Authors:  W G Dixon; K L Hyrich; K D Watson; M Lunt; J Galloway; A Ustianowski; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2009-10-22       Impact factor: 19.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.